Patent Counsel

Arent Fox's patent law blog examines the latest news, trends, and legal developments in the patent world.

Patent Counsel

Janine A. Carlan

Janine Carlan, Partner at Arent Fox
Janine A. Carlan
Partner
Washington, DC
202.715.8506

Janine Carlan, a partner at Arent Fox and a registered US patent attorney, concentrates in resolution of intellectual property disputes. Janine has extensive experience in litigating intellectual property matters involving a wide range of legal issues.

Client Work

Janine has represented clients in bench and jury trials throughout the United States, and has particular expertise in Hatch-Waxman cases and International Trade Commission (ITC) Section 337 cases. She has first chair experience in numerous federal district court cases, and has been involved in patent cases covering diverse areas of technology including pharmaceuticals, medical devices, electronics, software, Internet content delivery, automotive, chemical, manufacturing, furniture and plastics processing.

Janine was of counsel before the United States Supreme Court in the case The Holmes Group, Inc. v. Vornado Air Cir. Systems.

Janine has also represented clients in trademark litigation and in asserting or defending claims of trade secret misappropriation and unfair competition. She has represented clients in the banking, insurance, hotel, and automotive industries to protect their trademarks through litigation in federal court.

Previous Work

Prior to becoming an attorney, Janine worked as an engineer at FMC Pharmaceuticals, McNeil Consumer Products, and Astra Zeneca in the areas of regulatory affairs, research and development, and pharmaceutical manufacturing.

Publications, Presentations, and Recognitions

Publications

  • "Bioshield II: The proposed legislation includes controversial provisions for pharmaceutical companies," Pharma & Bio Ingredients; December 2005
  • "Vioxx: A Painful Decision," Pharma & Bio Ingredients; September / October 2005
  • "Two Key Decisions: The Merck and Purdue Cases Could Impact the Work of Every Pharmaceutical Researcher," Pharma & Bio Ingredients; July / August 2005
  • "Authorized Generics, Despite a Flurry of Activity, Controversy Continues to Surround the Category," Pharma & Bio Ingredients; May / June 2005
  • “IP Protection (in India and China) Intellectual Property Rights and Enforcement has been Troublesome for Decades, but Recent Dramatic Changes have Occurred,” Pharma & Bio Ingredients; January / February 2005
  • "Hatch-Waxman, A look back after 20 years of regulation and a look ahead to pending provisions,” Pharma & Bio Ingredients; December 2004
  • "New Medicare Law Brings New Considerations for “Paragraph IV Litigation,” Food and Drug Law Institute Update; March / April 2004

Presentations

  • “Workshop on Overcoming Elicit Bias,” American Conference Institute (ACI) Conference on Women Leaders in Life Sciences Law; Boston, MA; July 28-29, 2014
  • “Latest Developments in Pharma/Life Sciences Patent Litigation,” Fordham University School of Law IP Summit; New York, NY; November 18-19, 2013
  • “Purpose, Passion, and Performance — A New Era,” The Washington DC, Maryland, and Virginia (DMV) Diversity Council First Annual Women in Leadership Symposium; March 29, 2012
  • “Litigation and Technology and Intellectual Property Common Interest Agreements: Dangerous Liaisons?” Washington Metropolitan Area Corporate Counsel Association; McLean, VA; April 2011
  • “Litigating with Multiple ANDA Filers: Brand Name and Generic Perspectives,” American Conference Institute (ACI) Conference on Paragraph IV Disputes; San Francisco, CA; December 9, 2010
  • “Notable Decisions from the ITC,” University of Baltimore conference on the Domestic Impact of Intellectual Property in a Global Economy; Baltimore, MD; March 2010
  • “Secondary Consideration Experts: The Clinician,” ACI Paragraph IV On Trial, New York, NY; November 2009
  • “Implications of the Quanta v. LG Case;” Maryland State Bar Association Intellectual Property Association; webinar; January 2009
  • “Secondary Consideration Experts: The Clinician,” ACI Paragraph IV On Trial, New York, NY; November 2008
  • “Discovery in Paragraph IV Matters: Documents, Experts and Privilege – A Look from Both Sides,” ACI Conference on Paragraph IV Disputes; New York, NY; April 2007
  • "Patentability of ‘Reach-Through’ Claims: US, European and Japanese Patent Office Perspectives,” ACI Advanced Forum on Biotech Patents Conference in San Francisco, CA; October 2003

Recognition

  • National Diversity Council Recognized Janine as one of the Most Powerful and Influential Women of 2010.
 

Blog Posts by Janine A. Carlan

There are no blog posts by this author.

SUBSCRIBE

Add this blog to your RSS feed reader.

Arent Fox In Your Inbox
To subscribe to Arent Fox Alerts and other news, click here.

ABOUT ARENT FOX LLP

Arent Fox LLP, founded in 1942, is internationally recognized in core practice areas where business and government intersect. With more than 350 lawyers, the firm provides strategic legal counsel and multidisciplinary solutions to clients that range from Fortune 500 corporations to trade associations. The firm has offices in Los Angeles, New York, San Francisco, and Washington, DC.